Evidence map›Paper›PMID 22930518›Full record

ReviewJournal of medical virology2012

Review: Viral infections and mechanisms of thrombosis and bleeding.

M Goeijenbier, M van Wissen, C van de Weg, E Jong, V E A Gerdes, J C M Meijers, D P M Brandjes, E C M van Gorp

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Journal of medical virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04505774 phase4completednot on this mapstarted 2020, after this paper: background citation

A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19

TypeinterventionalSponsorMatthew Neal MDRan2020 to 2024Enrolled3,591ConditionsCovid19Armstheraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
NCT05286268 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Role of Ischemia Modified Albumin in Patients With COVID-19

TypeobservationalSponsorLarissa University HospitalRan2022 to 2022Enrolled194ConditionsCOVID-19ArmsIschemia Modified Albumin
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 3 syntheses or guidelines pooled it, 309 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prevalence and Risk Factors of Thromboembolism among Patients With Coronavirus Disease-19: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. New Directions in Infection-Associated Ischemic Stroke.Journal of clinical neurology (Seoul, Korea) · 2024
    Review
  19. Article
  20. Article

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

M GoeijenbierDepartment of Virology, Erasmus Medical Centre, University of Rotterdam, Rotterdam, The Netherlands. m.goeijenbier@erasmusmc.nl.
M van Wissen
C van de Weg
E Jong
V E A Gerdes
J C M Meijers
D P M Brandjes
E C M van Gorp
Slotervaartziekenhuis · NLErasmus University Rotterdam · NLAcademic Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infections are associated with coagulation disorders. All aspects of the coagulation cascade, primary hemostasis, coagulation, and fibrinolysis, can be affected. As a consequence, thrombosis and disseminated intravascular coagulation, hemorrhage, or both, may occur. Investigation of coagulation disorders as a consequence of different viral infections have not been performed uniformly. Common pathways are therefore not fully elucidated. In many severe viral infections there is no treatment other than supportive measures. A better understanding of the pathophysiology behind the association of viral infections and coagulation disorders is crucial for developing therapeutic strategies. This is of special importance in case of severe complications, such as those seen in hemorrhagic viral infections, the incidence of which is increasing worldwide. To date, only a few promising targets have been discovered, meaning the implementation in a clinical context is still hampered. This review discusses non-hemorrhagic and hemorrhagic viruses for which sufficient data on the association with hemostasis and related clinical features is available. This will enable clinicians to interpret research data and place them into a perspective.

Indexed as

HemorrhageHumansThrombosisVirus DiseasesViruses

Identifiers

PMID22930518
PMCPMC7166625
OpenAlexW2055602946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.